Search General Info
Search Education
Search Partnering Companies
![CEO 2023 Logo](/sites/default/files/2022-08/264423_BIO_22_CEO_Logo-V.png)
Vision: Expand patient access to therapeutic biologics with oral biologics in a pill modality.
Oral Platform: Bioengineered Probiotic Yeast Medicines (BioPYM) platform is a first-in-class new modality live yeast micro-factory enabling ORAL delivery of protein therapeutics to the gastrointestinal tract. BioPYM is engineered with a ‘plug & play’ genomic cassette to secrete any therapeutic protein "bottomless pipeline". Focus is on GI disorders such as infections, inflammation, cancer, diabetes and abdominal pain. We currently have >10 preclinical BioPYM candidates. C diff infection lead (FZ002) expected to enter clinical trials in 2023. Our second product for IBD (FZ006) is validated in multiple animal IBD models and demonstrates superiority to Humira®. BioPYM competitive advantages include 1) manufacturing, 2) clinical, and 3) patient QoL.
Ask: Fzata past funding includes $1M (VC) and $17M (non-dilutive NIH). We are now raising $33M series A and also seeking pharma partners.
Oral Platform: Bioengineered Probiotic Yeast Medicines (BioPYM) platform is a first-in-class new modality live yeast micro-factory enabling ORAL delivery of protein therapeutics to the gastrointestinal tract. BioPYM is engineered with a ‘plug & play’ genomic cassette to secrete any therapeutic protein "bottomless pipeline". Focus is on GI disorders such as infections, inflammation, cancer, diabetes and abdominal pain. We currently have >10 preclinical BioPYM candidates. C diff infection lead (FZ002) expected to enter clinical trials in 2023. Our second product for IBD (FZ006) is validated in multiple animal IBD models and demonstrates superiority to Humira®. BioPYM competitive advantages include 1) manufacturing, 2) clinical, and 3) patient QoL.
Ask: Fzata past funding includes $1M (VC) and $17M (non-dilutive NIH). We are now raising $33M series A and also seeking pharma partners.
![](/sites/default/files/hubb_images/6588/attachments/%2520-%2520f1_Fzata_2C_20Inc__1a8c73f2.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
FZ002 for C diff infection
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
![photo](/sites/default/files/hubb_images/6588/photos/user1.Smith.913db503.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved